m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03202
 [1]
m6A modification TUG1 TUG1 ALKBH5 Demethylation : m6A sites Indirect Enhancement Histone modification H3K9me2 EHMT2 SH3BGRL
m6A Modification:
m6A Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
m6A Target Taurine up-regulated 1 protein (TUG1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone-lysine N-methyltransferase EHMT2 (EHMT2) WRITER View Details
Regulated Target Histone H3 lysine 9 dimethylation (H3K9me2) View Details
Downstream Gene SH3BGRL View Details
Crosstalk Relationship m6A  →  Histone modification Enhancement
Crosstalk Mechanism m6A modification indirectly regulates histone modification through downstream signaling pathways
Crosstalk Summary ALKBH5 removed m6A modification to stabilize Taurine up-regulated 1 protein (TUG1) expression in a YTHDF2-dependent manner, enhancing EHMT2-mediated Histone H3 lysine 9 dimethylation (H3K9me2) levels on the SH3BGRL promoter and suppressing SH3BGRL expression, thus promoting ADR resistance in AML cells.
Responsed Disease Acute myeloid leukaemia ICD-11: 2A60
 Disease Info 
Responsed Drug Adriamycin
 Drug Info 
In-vitro Model
 HL-60 Adult acute myeloid leukemia Homo sapiens CVCL_0002
HL-60 Adult acute myeloid leukemia Homo sapiens CVCL_0002
HEL Erythroleukemia Homo sapiens CVCL_0001
K-562 Chronic myelogenous leukemia Homo sapiens CVCL_0004
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Histone-lysine N-methyltransferase EHMT2 (EHMT2) 7 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name MS012 Preclinical [2]
Synonyms
CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 137348638
TTD: DJ1Q9B
 Compound Name BIX-01294 Preclinical [3]
Synonyms
BIX01294; BIX 01294
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 67 nM
External Link
CID: 25150857
TTD: D06PPL
 Compound Name A-366 Preclinical [4]
Synonyms
A 366; A366
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
CID: 76285486
TTD: D0C5EG
 Compound Name UNC0321 Investigative [5]
Synonyms
UNC-0321; UNC 0321
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 9000 nM
External Link
CID: 46901937
TTD: D0CX4W
 Compound Name BRD9539 Investigative [6]
Synonyms
BRD-9539; BRD 9539
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1500 nM
External Link
CID: 73755260
TTD: D0RO9T
 Compound Name UNC0642 Investigative [7]
Synonyms
1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, > KB-146019; J-008448
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 2.5 nM
External Link
CID: 53315878
TTD: D0BI4T
 Compound Name UNC0638 Investigative [8]
Synonyms
1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 3.7 nM
External Link
CID: 46224516
TTD: D0GK7A
2A60: Acute myeloid leukaemia 283 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Atezolizumab Approved [9]
External Link
TTD: D0YM2K
 Compound Name ENASIDENIB MESYLATE Approved [10]
Synonyms
UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541
    Click to Show/Hide
External Link
CID: 90480031
TTD: D0WH4P
 Compound Name Lestaurtinib Approved (orphan drug) [11]
Synonyms
A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)
    Click to Show/Hide
External Link
CID: 126565
TTD: D0V9WF
DrugBank: DB06469
 Compound Name Motixafortide Approved [12]
External Link
CID: 91865076
TTD: D0T6CN
DrugBank: DB14939
 Compound Name ARN-509 Approved [13]
Synonyms
Arn-509 (AR inhibitor)
    Click to Show/Hide
External Link
CID: 24872560
TTD: D0S7LG
DrugBank: DB11901
 Compound Name DEOXYCYTIDINE Approved [14]
Synonyms
Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993
    Click to Show/Hide
External Link
CID: 13711
TTD: D0RX7Z
DrugBank: DB02594
 Compound Name Bestatin Approved [15]
Synonyms
Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid
    Click to Show/Hide
External Link
CID: 72172
TTD: D0RA5Q
DrugBank: DB03424
 Compound Name Tagraxofusp Approved [13]
Synonyms
Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
    Click to Show/Hide
External Link
TTD: D0R7NI
 Compound Name Uracil mustard Approved [16]
Synonyms
Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol
    Click to Show/Hide
External Link
CID: 6194
TTD: D0J9UN
DrugBank: DB00791
 Compound Name Tisagenlecleucel Application submitted [17]
Synonyms
Tisagenlecleucel-T
    Click to Show/Hide
External Link
TTD: D0IM6T
 Compound Name Olutasidenib Approved [9]
Synonyms
NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1
    Click to Show/Hide
External Link
CID: 118955396
TTD: D07VYP
 Compound Name Midostaurin Approved [18]
Synonyms
PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251
    Click to Show/Hide
External Link
CID: 9829523
TTD: D07NVU
DrugBank: DB06595
 Compound Name Quizartinib Approved [19]
Synonyms
Quizartinib
    Click to Show/Hide
External Link
CID: 24889392
TTD: D07KYT
DrugBank: DB12874
 Compound Name Ivosidenib Approved [19]
Synonyms
UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767
    Click to Show/Hide
External Link
CID: 71657455
TTD: D07DCG
DrugBank: DB14568
 Compound Name Gemtuzumab ozogamicin Approved [20]
Synonyms
Mylotarg (TN)
    Click to Show/Hide
External Link
TTD: D06EWO
 Compound Name Gilteritinib Approved [13]
Synonyms
UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199
    Click to Show/Hide
External Link
CID: 49803313
TTD: D04KZY
DrugBank: DB12141
 Compound Name Thioguanine Approved [21]
Synonyms
6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)
    Click to Show/Hide
External Link
CID: 2723601
TTD: D02ZXM
DrugBank: DB00352
 Compound Name Daunorubicin Approved [22]
Synonyms
Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline
    Click to Show/Hide
External Link
CID: 30323
TTD: D01XWG
DrugBank: DB00694
 Compound Name Idarubicin Approved [23]
Synonyms
DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin
    Click to Show/Hide
External Link
CID: 42890
TTD: D01XDL
DrugBank: DB01177
 Compound Name Aclarubicin Approved [24]
Synonyms
Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A
    Click to Show/Hide
External Link
CID: 451415
TTD: D01UBX
DrugBank: DB11617
 Compound Name Magrolimab Phase 3 [25]
Synonyms
GS-4721
    Click to Show/Hide
External Link
TTD: DN5CM6
 Compound Name DSP-7888 Phase 2 [9]
External Link
TTD: DE5L6B
 Compound Name 131I-labelled aCD45 Phase 3 [26]
External Link
TTD: DC8EN0
 Compound Name ATIR101 Phase 3 [27]
External Link
TTD: D6O2PN
 Compound Name Dociparstat sodium Phase 3 [28]
Synonyms
DSTAT
    Click to Show/Hide
External Link
TTD: D5VRX2
 Compound Name Iomab-B CD45 Phase 3 [9]
External Link
TTD: D0Z0MI
 Compound Name Tasisulam Phase 3 [29]
Synonyms
Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly
    Click to Show/Hide
External Link
CID: 10160238
TTD: D0X0KM
DrugBank: DB11941
 Compound Name Vadastuximab talirine Phase 3 [17]
Synonyms
Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5
    Click to Show/Hide
External Link
CID: 122706909
TTD: D0W2BF
 Compound Name Abexinostat Phase 3 [9]
Synonyms
PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide
    Click to Show/Hide
External Link
CID: 11749858
TTD: D0V0SL
DrugBank: DB12565
 Compound Name Peginterferon lambda-1a Phase 3 [30]
Synonyms
BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb
    Click to Show/Hide
External Link
TTD: D0T6IN
 Compound Name CPX-351 Phase 3 [19]
Synonyms
Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
    Click to Show/Hide
External Link
CID: 11422859
TTD: D0SB1B
 Compound Name BYM338 Phase 2/3 [31]
External Link
TTD: D0S5FF
 Compound Name SGI110 Phase 3 [32]
External Link
CID: 137295284
TTD: D0Q5KZ
 Compound Name Elacytarabine Phase 3 [33]
Synonyms
Elacyt (TN)
    Click to Show/Hide
External Link
CID: 6438895
TTD: D0PY5D
DrugBank: DB05494
 Compound Name RG7388 Phase 3 [34]
Synonyms
Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856
    Click to Show/Hide
External Link
CID: 53358942
TTD: D0OC4O
DrugBank: DB12325
 Compound Name Galinpepimut-S Phase 3 [35]
External Link
TTD: D0M9OO
 Compound Name Pracinostat Phase 3 [19]
Synonyms
929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-
    Click to Show/Hide
External Link
CID: 49855250
TTD: D0L2UQ
DrugBank: DB05223
 Compound Name DFP-10917 Phase 3 [9]
External Link
CID: 119184
TTD: D0KE1F
DrugBank: DB11667
 Compound Name AG-881 Phase 1 [9]
Synonyms
Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop
    Click to Show/Hide
External Link
CID: 117817422
TTD: D0K9PC
 Compound Name AG-221 Phase 1/2 [36]
Synonyms
AG-221 (IDH2 inhibitor)
    Click to Show/Hide
External Link
CID: 89683805
TTD: D0K7FT
DrugBank: DB13874
 Compound Name CP-868596 Phase 3 [9]
Synonyms
Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
    Click to Show/Hide
External Link
CID: 10366136
TTD: D0J1GR
DrugBank: DB11832
 Compound Name Rydaptmidostaurin Phase 3 [9]
External Link
TTD: D0H6BS
 Compound Name Sapacitabine Phase 3 [37]
Synonyms
CYC682
    Click to Show/Hide
External Link
CID: 153970
TTD: D0D4RF
DrugBank: DB06365
 Compound Name S-110 Phase 3 [32]
Synonyms
DNA demethylating agent (myelodysplastic syndrome), Supergen
    Click to Show/Hide
External Link
TTD: D0A2BO
 Compound Name VAL-083 Phase 1/2 [38]
Synonyms
Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6
    Click to Show/Hide
External Link
CID: 15942827
TTD: D0A1IL
DrugBank: DB12873
 Compound Name CC-486 Phase 3 [9]
Synonyms
AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue
    Click to Show/Hide
External Link
CID: 9840076
TTD: D09NTC
 Compound Name Hu5F9-G4 Phase 3 [17]
External Link
TTD: D09JYL
 Compound Name Iomab-B Phase 3 [39]
Synonyms
Iomab-B (TN)
    Click to Show/Hide
External Link
TTD: D08BBL
 Compound Name PEG arginine deiminase Phase 1 [9]
Synonyms
ADI-PEG 20
    Click to Show/Hide
External Link
TTD: D07UAS
 Compound Name CPI-613 Phase 3 [19]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Zarnestra Phase 3 [40]
Synonyms
JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
    Click to Show/Hide
External Link
CID: 159324
TTD: D07NPS
DrugBank: DB04960
 Compound Name LMT-X Phase 3 [41]
Synonyms
Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx
    Click to Show/Hide
External Link
TTD: D05XDZ
 Compound Name Elesclomol Phase 3 [42]
Synonyms
488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum
    Click to Show/Hide
External Link
CID: 300471
TTD: D05IRV
DrugBank: DB05719
 Compound Name GMI-1271 Phase 3 [43]
Synonyms
Uproleselan
    Click to Show/Hide
External Link
CID: 71600085
TTD: D03PWD
DrugBank: DB14829
 Compound Name AT-406 Phase 3 [44]
Synonyms
1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143
    Click to Show/Hide
External Link
CID: 25022340
TTD: D03MXK
 Compound Name PR1 peptide antigen vaccine Phase 3 [45]
Synonyms
PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company
    Click to Show/Hide
External Link
TTD: D03GHV
 Compound Name CPI-0610 Phase 3 [9]
External Link
CID: 57389999
TTD: D01LVE
 Compound Name SNS-595 Phase 3 [46]
Synonyms
Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
    Click to Show/Hide
External Link
CID: 9952884
TTD: D00NVM
DrugBank: DB11999
 Compound Name Selinexor Phase 3 [19]
Synonyms
Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F
    Click to Show/Hide
External Link
CID: 71481097
TTD: D00LNW
DrugBank: DB11942
 Compound Name Volasertib Phase 3 [19]
Synonyms
755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947
    Click to Show/Hide
External Link
CID: 10461508
TTD: D00BYM
DrugBank: DB12062
 Compound Name Rivo-cel Phase 2/3 [47]
Synonyms
BPX-501
    Click to Show/Hide
External Link
TTD: D4OU6H
 Compound Name CLL1 CAR-T Cell Phase 2/3 [48]
External Link
TTD: D0RF4J
 Compound Name NLG8189 Phase 2/3 [9]
Synonyms
1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189
    Click to Show/Hide
External Link
CID: 405012
TTD: D0B5HS
DrugBank: DB12827
 Compound Name CD123/CLL1 CAR-T Cells Phase 2/3 [48]
External Link
TTD: D04GGG
 Compound Name K-NK002 Phase 2 [49]
Synonyms
CSTD-002-NK
    Click to Show/Hide
External Link
TTD: DTU7W2
 Compound Name Dilanubicel Phase 2 [50]
Synonyms
NLA101
    Click to Show/Hide
External Link
TTD: DS01GZ
 Compound Name DS-3201b Phase 2 [51]
Synonyms
Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551
    Click to Show/Hide
External Link
CID: 126481870
TTD: DNM79H
 Compound Name BST-236 Phase 2 [52]
Synonyms
Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine
    Click to Show/Hide
External Link
CID: 135390942
TTD: DGN26L
 Compound Name Zelenoleucel Phase 2 [53]
External Link
TTD: D4T8JV
 Compound Name CX-01 Phase 2 [9]
External Link
TTD: D0ZI4L
 Compound Name LY2090314 Phase 2 [54]
Synonyms
603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt
    Click to Show/Hide
External Link
CID: 10029385
TTD: D0Z1DH
DrugBank: DB11913
 Compound Name Flotetuzumab Phase 2 [55]
External Link
TTD: D0YA1B
 Compound Name BGB-324 Phase 1/2 [19]
Synonyms
BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio
    Click to Show/Hide
External Link
TTD: D0X9VR
 Compound Name PTX-200 Phase 2 [9]
Synonyms
Plant-derived antiparkinsonian, Phytrix
    Click to Show/Hide
External Link
TTD: D0X7CV
 Compound Name LY2523355 Phase 2 [56]
Synonyms
Litronesib
    Click to Show/Hide
External Link
CID: 25167017
TTD: D0W9SL
DrugBank: DB11861
 Compound Name Prexigebersen Phase 2 [9]
Synonyms
Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4
    Click to Show/Hide
External Link
CID: 123132008
TTD: D0W3GR
 Compound Name ALT-801 Phase 2 [57]
Synonyms
ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
    Click to Show/Hide
External Link
TTD: D0V5JH
 Compound Name ENMD-2076 Phase 2 [58]
Synonyms
934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159
    Click to Show/Hide
External Link
CID: 16041424
TTD: D0S7HM
 Compound Name FPI-01 Phase 2 [59]
Synonyms
WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0RG8Z
 Compound Name Inecalcitol oral Phase 2 [9]
Synonyms
Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics
    Click to Show/Hide
External Link
CID: 6915835
TTD: D0R8IE
DrugBank: DB04796
 Compound Name Eryaspase Phase 2 [9]
External Link
TTD: D0P0SD
 Compound Name ALXN6000 Phase 2 [17]
Synonyms
Samalizumab
    Click to Show/Hide
External Link
TTD: D0OY9L
 Compound Name BI 2536 Phase 2 [60]
Synonyms
BI2536, BI 2536
    Click to Show/Hide
External Link
CID: 11364421
TTD: D0O0LQ
 Compound Name MK8242 Phase 2 [61]
External Link
TTD: D0NT6P
 Compound Name Leukemia DNA vaccine Phase 2 [62]
External Link
TTD: D0N6UA
 Compound Name Anti-CD45 mAb 131I-BC8 Phase 2 [19]
External Link
TTD: D0N4NH
 Compound Name BREQUINAR Phase 1/2 [63]
Synonyms
96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum
    Click to Show/Hide
External Link
CID: 57030
TTD: D0N3XT
DrugBank: DB03523
 Compound Name Leukemia cancer vaccine Phase 2 [64]
External Link
TTD: D0M0OT
 Compound Name ADCT-301 Phase 1 [9]
Synonyms
camidanlumab tesirine
    Click to Show/Hide
External Link
TTD: D0LL1N
 Compound Name Flavopiridol Phase 2 [19]
Synonyms
FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
    Click to Show/Hide
External Link
CID: 5287969
TTD: D0LF1U
DrugBank: DB03496
 Compound Name BP-100-1-01 Phase 2 [65]
External Link
TTD: D0L3KA
 Compound Name IRX-2 Phase 2 [66]
External Link
TTD: D0KS6F
 Compound Name Cenersen Phase 2 [67]
External Link
CID: 56841947
TTD: D0K4VW
 Compound Name Lirilumab Phase 2 [68]
External Link
TTD: D0I7PU
 Compound Name LOR-2040 Phase 2 [69]
External Link
TTD: D0I7NG
 Compound Name Sodium butyrate Phase 2 [70]
Synonyms
Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)
    Click to Show/Hide
External Link
CID: 5222465
TTD: D0I7IB
 Compound Name GRNVAC1 Phase 2 [71]
External Link
TTD: D0I6RI
 Compound Name H3B-8800 Phase 1 [9]
External Link
TTD: D0H7BF
 Compound Name GS-9973 Phase 2 [9]
Synonyms
Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385
    Click to Show/Hide
External Link
CID: 59473233
TTD: D0G9AW
DrugBank: DB12121
 Compound Name ALT-803 Phase 2 [72]
Synonyms
IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
    Click to Show/Hide
External Link
TTD: D0FD7H
 Compound Name CHR-2797 Phase 2 [73]
Synonyms
Tosedostat; Tosedostat, CHR2797, CHR-2797
    Click to Show/Hide
External Link
CID: 15547703
TTD: D0F2JS
DrugBank: DB11781
 Compound Name HTERT RNA vaccine Phase 2 [74]
External Link
TTD: D0CQ1X
 Compound Name MB-102 Phase 2 [17]
Synonyms
Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0
    Click to Show/Hide
External Link
CID: 53389120
TTD: D0C3JB
 Compound Name phorbol 12-myristate 13-acetate Phase 2 [9]
Synonyms
TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate
    Click to Show/Hide
External Link
CID: 27924
TTD: D09DHT
 Compound Name AEB1102 Phase 1 [9]
External Link
TTD: D08WQU
 Compound Name Ifabotuzumab Phase 2 [17]
External Link
TTD: D08NZG
 Compound Name BP1001 Phase 2 [19]
External Link
TTD: D08IVF
 Compound Name AS-101 Phase 2 [75]
Synonyms
Ossirene; Tellaxium trichloride glycol; IVX-Q-101
    Click to Show/Hide
External Link
CID: 11260998
TTD: D08EAI
 Compound Name ALRN-6924 Phase 2 [9]
External Link
TTD: D07UKT
 Compound Name GO-203-2c Phase 2 [9]
External Link
TTD: D07OAD
 Compound Name Talacotuzumab Phase 2 [17]
Synonyms
JNJ 473; JNJ 56022473; TAL
    Click to Show/Hide
External Link
TTD: D07MGC
 Compound Name AST-VAC1 Phase 2 [76]
External Link
TTD: D07KAB
 Compound Name Lomab B Phase 2 [77]
Synonyms
BCS-I-131 construct
    Click to Show/Hide
External Link
TTD: D07CQW
 Compound Name Fipamezole Phase 2 [78]
Synonyms
150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole
    Click to Show/Hide
External Link
CID: 213041
TTD: D05LGX
DrugBank: DB06585
 Compound Name PR104 Phase 2 [79]
Synonyms
851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5- dinitro-N-(2-(phosphonooxy)ethyl)-
    Click to Show/Hide
External Link
CID: 11455973
TTD: D05CFG
DrugBank: DB05968
 Compound Name BI-836858 Phase 1/2 [9]
External Link
TTD: D04MGW
 Compound Name Ficlatuzumab Phase 2 [9]
Synonyms
AV-299
    Click to Show/Hide
External Link
TTD: D03UBW
 Compound Name K562/GM-CSF Phase 2 [80]
Synonyms
GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins
    Click to Show/Hide
External Link
TTD: D03PRC
 Compound Name PCM-075 Phase 2 [9]
Synonyms
Onvansertib
    Click to Show/Hide
External Link
CID: 49792852
TTD: D03HUX
DrugBank: DB15110
 Compound Name Actimab-A Phase 2 [17]
External Link
TTD: D03HSA
 Compound Name IMG-7289 Phase 2 [9]
Synonyms
KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide
    Click to Show/Hide
External Link
CID: 122460381
TTD: D03EOZ
DrugBank: DB15126
 Compound Name WT1-targeted autologous dendritic cell vaccine Phase 2 [81]
Synonyms
WT1-targeted autologous dendritic cell vaccine (cancer)
    Click to Show/Hide
External Link
TTD: D02MLO
 Compound Name AZD-4877 Phase 2 [82]
Synonyms
Anticancer therapeutic (solid tumors), AstraZeneca
    Click to Show/Hide
External Link
CID: 10368812
TTD: D02AAO
DrugBank: DB11671
 Compound Name IPH-2102 Phase 2 [83]
External Link
TTD: D00RYU
 Compound Name ASP7517 Phase 1/2 [84]
External Link
TTD: DYM1J4
 Compound Name CG-806 Phase 1/2 [85]
Synonyms
1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-
    Click to Show/Hide
External Link
CID: 66981446
TTD: DT3BA1
 Compound Name KO-539 Phase 1/2 [86]
Synonyms
UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6
    Click to Show/Hide
External Link
CID: 138497449
TTD: DS4JE8
 Compound Name SAR440234 Phase 1/2 [87]
External Link
TTD: DL1FG3
 Compound Name HM43239 Phase 1/2 [88]
External Link
TTD: DI1VM3
 Compound Name Annamycin Phase 1/2 [9]
Synonyms
92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903
    Click to Show/Hide
External Link
CID: 115212
TTD: DCT2Q3
DrugBank: DB06420
 Compound Name ONO-7475 Phase 1/2 [89]
Synonyms
1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide
    Click to Show/Hide
External Link
CID: 90645873
TTD: DA1MG8
 Compound Name FF-10101 Phase 1/2 [90]
Synonyms
1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-
    Click to Show/Hide
External Link
CID: 90052320
TTD: D28HJI
 Compound Name SL-401 Phase 1/2 [91]
External Link
TTD: D0Z2ZY
 Compound Name SEL-24 Phase 1/2 [9]
Synonyms
Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita
    Click to Show/Hide
External Link
TTD: D0X8ID
 Compound Name SEL24 Phase 1/2 [92]
Synonyms
MEN1703
    Click to Show/Hide
External Link
TTD: D0V2ZC
 Compound Name CD38-specific gene-engineered T cells Phase 1/2 [93]
External Link
TTD: D0UJ3C
 Compound Name HuM-195-Ac-225 Phase 1/2 [94]
Synonyms
HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab
    Click to Show/Hide
External Link
TTD: D0TV6H
 Compound Name NEXI-001 Phase 1/2 [95]
External Link
TTD: D0SZT3
 Compound Name INCB59872 Phase 1/2 [9]
External Link
TTD: D0R7CD
 Compound Name MG7-CART Phase 1/2 [96]
External Link
TTD: D0Q5GK
 Compound Name PRI-724 Phase 1/2 [97]
External Link
CID: 71509318
TTD: D0Q0ZY
DrugBank: DB15034
 Compound Name CART-123 cells Phase 1/2 [98]
External Link
TTD: D0N6PE
 Compound Name OXi4503 Phase 1/2 [9]
Synonyms
Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt
    Click to Show/Hide
External Link
CID: 6918545
TTD: D0N4HQ
 Compound Name CIK-CAR.CD19 Phase 1/2 [9]
External Link
TTD: D0M2XK
 Compound Name RhH1.3 Phase 1/2 [99]
Synonyms
Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec
    Click to Show/Hide
External Link
TTD: D0K6UG
 Compound Name JTCR016 Phase 1/2 [17]
External Link
TTD: D0J6AJ
 Compound Name Muc1-specific gene-engineered T cells Phase 1/2 [93]
External Link
TTD: D0IQ3E
 Compound Name Lintuzumab Ac-225 Phase 1/2 [100]
Synonyms
Actimab-A (TN)
    Click to Show/Hide
External Link
TTD: D0HV7A
 Compound Name CD33-specific gene-engineered T cells Phase 1/2 [93]
External Link
TTD: D0G9MY
 Compound Name CD19 specific CAR T cells Phase 1/2 [101]
External Link
TTD: D0FR3J
 Compound Name EPZ-5676 Phase 1/2 [102]
Synonyms
pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine
    Click to Show/Hide
External Link
CID: 57345410
TTD: D0C6GK
DrugBank: DB12920
 Compound Name BSK01 Phase 1/2 [17]
External Link
TTD: D0AZ1N
 Compound Name CNDO-109 Phase 1/2 [19]
External Link
TTD: D0A0CY
 Compound Name DT388IL-3 Phase 1/2 [103]
External Link
TTD: D08MKR
 Compound Name PLX2853 Phase 1/2 [104]
External Link
TTD: D07GHA
 Compound Name CWP232291 Phase 1/2 [105]
External Link
TTD: D07AYI
 Compound Name BPX-501 Phase 1/2 [9]
External Link
TTD: D06LYI
 Compound Name RTX-240 Phase 1/2 [106]
External Link
TTD: D05ZBV
 Compound Name G0-203-2c Phase 1/2 [107]
External Link
TTD: D04WHM
 Compound Name CD123-specific gene-engineered T cells Phase 1/2 [93]
External Link
TTD: D04MLR
 Compound Name CD56-specific gene-engineered T cells Phase 1/2 [93]
External Link
TTD: D03HML
 Compound Name OTX-015 Phase 1/2 [108]
Synonyms
MK 8628
    Click to Show/Hide
External Link
CID: 9936746
TTD: D02YNI
DrugBank: DB15189
 Compound Name FF-10501-01 Phase 1/2 [9]
External Link
TTD: D02BVW
 Compound Name SGN-CD33A Phase 1/2 [19]
External Link
TTD: D01KKI
 Compound Name CLL1-specific gene-engineered T cells Phase 1/2 [93]
External Link
TTD: D00QWK
 Compound Name CLT030 Phase 1 [109]
External Link
TTD: DW01LJ
 Compound Name FT500 Phase 1 [110]
External Link
TTD: DSYM73
 Compound Name 225Ac-labelled aCD33 Phase 1 [111]
External Link
TTD: DSI4G9
 Compound Name PRGN-3006 Phase 1 [112]
External Link
TTD: DR0L8A
 Compound Name GEM333 Phase 1 [113]
External Link
TTD: DQD1T2
 Compound Name VOB560 Phase 1 [114]
Synonyms
S 65487
    Click to Show/Hide
External Link
TTD: DP63FS
 Compound Name SEL120 Phase 1 [115]
Synonyms
SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride
    Click to Show/Hide
External Link
CID: 73776232
TTD: DOJG79
 Compound Name NKX101 Phase 1 [116]
External Link
TTD: DOBZ63
 Compound Name AMG 673 Phase 1 [9]
External Link
TTD: DNS2P1
 Compound Name SAR443579 Phase 1 [117]
External Link
TTD: DMKG40
 Compound Name IO-202 Phase 1 [118]
External Link
TTD: DM9GO4
 Compound Name CYC140 Phase 1 [119]
Synonyms
Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-
    Click to Show/Hide
External Link
CID: 57336523
TTD: DK26FL
 Compound Name SKI-G-801 Phase 1 [120]
External Link
TTD: DIA08F
 Compound Name CC-90002 Phase 1 [17]
External Link
TTD: DI8WC4
 Compound Name TAS-1440 Phase 1 [121]
External Link
TTD: DI17KH
 Compound Name RG6007 Phase 1 [122]
External Link
TTD: DHWF68
 Compound Name CB-5339 Phase 1 [123]
External Link
TTD: DFC0V4
 Compound Name SAR445419 Phase 1 [124]
External Link
TTD: DCQ6L4
 Compound Name AB-110 Phase 1 [125]
External Link
TTD: DC6LS1
 Compound Name LP-108 Phase 1 [126]
External Link
TTD: DBY42T
 Compound Name H3B-8800 Phase 1 [127]
Synonyms
(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017
    Click to Show/Hide
External Link
CID: 92135969
TTD: DB5O1U
DrugBank: DB14017
 Compound Name CD123-CD33 Ccar Phase 1 [128]
External Link
TTD: DB4C5H
 Compound Name JNJ-63709178 Phase 1 [9]
External Link
TTD: D9TG4H
 Compound Name JNJ-67571244 Phase 1 [129]
External Link
TTD: D9OZ3B
 Compound Name AMG 427 Phase 1 [130]
External Link
TTD: D91CMX
 Compound Name AMG 330 Phase 1 [9]
External Link
TTD: D8AOC1
 Compound Name ABBV-184 Phase 1 [131]
External Link
TTD: D7QHV6
 Compound Name MIK665 Phase 1 [132]
Synonyms
1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5
    Click to Show/Hide
External Link
CID: 118157243
TTD: D7LC8N
 Compound Name FT538 Phase 1 [133]
External Link
TTD: D79JZU
 Compound Name BGB-11417 Phase 1 [134]
External Link
TTD: D74BRK
 Compound Name SEA-CD70 Phase 1 [135]
External Link
TTD: D6H9TE
 Compound Name CLL1-CD33 cCART cell therapy Phase 1 [136]
External Link
TTD: D5T9GZ
 Compound Name KITE-222 Phase 1 [137]
External Link
TTD: D4UQ2B
 Compound Name CYAD-02 Phase 1 [138]
External Link
TTD: D2Z7EL
 Compound Name GDX012 Phase 1 [139]
External Link
TTD: D2V9RQ
 Compound Name APVO436 Phase 1 [140]
External Link
TTD: D2GY5C
 Compound Name LAM-003 Phase 1 [9]
External Link
TTD: D20IMG
 Compound Name IMGN779 Phase 1 [9]
External Link
TTD: D0ZR1Z
 Compound Name BPX-701 Phase 1 [17]
External Link
TTD: D0ZA1K
 Compound Name BMS-936564 Phase 1 [141]
External Link
TTD: D0Z8JR
 Compound Name UCART123 Phase 1 [9]
External Link
TTD: D0Z7QK
 Compound Name FF-10101-01 Phase 1 [9]
External Link
TTD: D0YQ9I
 Compound Name CART-56 cells Phase 1 [142]
External Link
TTD: D0YH5L
 Compound Name AVB-S6-500 Phase 1 [9]
External Link
TTD: D0Y5QA
 Compound Name BB-MPI-03 Phase 1 [76]
External Link
TTD: D0W1TL
 Compound Name ONO-7475 Phase 1 [9]
External Link
TTD: D0VH4T
 Compound Name LC-1 Phase 1 [143]
Synonyms
Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix
    Click to Show/Hide
External Link
TTD: D0V5AL
 Compound Name CART123 cells Phase 1 [144]
External Link
TTD: D0R5NU
 Compound Name NKR-2 cells Phase 1 [145]
External Link
TTD: D0QR2K
 Compound Name CART-33 cells Phase 1 [142]
External Link
TTD: D0P6YN
 Compound Name BI-811283 Phase 1 [146]
External Link
TTD: D0P5IZ
 Compound Name INNO-305 Phase 1 [147]
External Link
TTD: D0P2ZY
 Compound Name IGN523 Phase 1 [148]
External Link
TTD: D0OQ5R
 Compound Name CART-34 cells Phase 1 [142]
External Link
TTD: D0NY1Y
 Compound Name CM-CS1 T-cell Phase 1 [149]
External Link
TTD: D0NC9M
 Compound Name Mivebresib Phase 1 [9]
Synonyms
ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815
    Click to Show/Hide
External Link
CID: 71600087
TTD: D0M2TS
 Compound Name AMV564 Phase 1 [9]
External Link
TTD: D0LP7U
 Compound Name SAR-103168 Phase 1 [150]
External Link
TTD: D0LO5N
 Compound Name DS-3201 Phase 1 [9]
Synonyms
QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione
    Click to Show/Hide
External Link
CID: 22627096
TTD: D0LG8T
 Compound Name PF-06747143 Phase 1 [17]
External Link
TTD: D0LC5L
 Compound Name DCLL9718S Phase 1 [9]
External Link
TTD: D0K6JZ
 Compound Name CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells Phase 1 [151]
External Link
TTD: D0JX7M
 Compound Name CSL-362 Phase 1 [152]
Synonyms
CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3
    Click to Show/Hide
External Link
TTD: D0JF9Z
 Compound Name AMG 176 Phase 1 [153]
Synonyms
JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-
    Click to Show/Hide
External Link
CID: 118910268
TTD: D0I5DP
 Compound Name XmAb14045 Phase 1 [9]
External Link
TTD: D0I4BK
 Compound Name SY-1425 Phase 1 [9]
External Link
TTD: D0HY3D
 Compound Name AGS62P1 Phase 1 [9]
Synonyms
AGS-62P1
    Click to Show/Hide
External Link
TTD: D0H3ND
 Compound Name CART-117 cells Phase 1 [142]
External Link
TTD: D0E0SH
 Compound Name CART-Muc1 cells Phase 1 [142]
External Link
TTD: D0DJ8S
 Compound Name BAY1436032 Phase 1 [9]
Synonyms
RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid
    Click to Show/Hide
External Link
CID: 118310260
TTD: D0C6RM
 Compound Name CD33-CAR-T Cell Phase 1 [154]
External Link
TTD: D0C4GN
 Compound Name CART-123 cells Phase 1 [142]
External Link
TTD: D0AW4T
 Compound Name FATE-NK100 Phase 1 [9]
External Link
TTD: D0A9GE
 Compound Name CC-90009 Phase 1 [9]
External Link
TTD: D09WIR
 Compound Name NKR-2 CAR-T Cells Phase 1 [155]
External Link
TTD: D08YHE
 Compound Name Anti-CEA CAR-T cells Phase 1 [156]
External Link
TTD: D08UVN
 Compound Name RG7775 Phase 1 [157]
External Link
TTD: D08TNG
 Compound Name OTSSP167 Phase 1 [9]
Synonyms
OTSSP 167; OTSSP-167; AMX10201
    Click to Show/Hide
External Link
CID: 135398499
TTD: D08FIX
 Compound Name IMC-EB10 Phase 1 [158]
Synonyms
Anti-Flt-3 Mab
    Click to Show/Hide
External Link
TTD: D07ZNF
 Compound Name TCN-P Phase 1 [159]
Synonyms
TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594
    Click to Show/Hide
External Link
CID: 43860
TTD: D07TWK
DrugBank: DB14636
 Compound Name CART-38 cells Phase 1 [142]
External Link
TTD: D06OES
 Compound Name ABBV-744 Phase 1 [9]
Synonyms
OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318
    Click to Show/Hide
External Link
CID: 132010322
TTD: D05ICT
 Compound Name AGS-67E Phase 1 [17]
External Link
TTD: D04MBK
 Compound Name PNK-007 Phase 1 [17]
External Link
TTD: D03IRG
 Compound Name GSK-2130579A Phase 1 [160]
Synonyms
Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline
    Click to Show/Hide
External Link
TTD: D02JEW
 Compound Name SGN-CD123A Phase 1 [9]
External Link
TTD: D01BRD
 Compound Name IM23 Phase 1 [161]
External Link
TTD: D00HAN
 Compound Name Anti-CD33 Phase 1 [9]
External Link
TTD: D00DIB
 Compound Name KW-2449 Phase 1 [162]
Synonyms
Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo
    Click to Show/Hide
External Link
CID: 11427553
TTD: D00ABO
 Compound Name CAR-T cells targeting CD56 Clinical trial [163]
External Link
TTD: D0V6WW
 Compound Name CAR-T cells targeting CD38 Clinical trial [163]
External Link
TTD: D0V6WU
 Compound Name Valspodar Discontinued in Phase 3 [164]
External Link
CID: 5281884
TTD: D09TGX
DrugBank: DB11869
 Compound Name LY335979 Discontinued in Phase 3 [165]
Synonyms
Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride
    Click to Show/Hide
External Link
CID: 153997
TTD: D06DCL
 Compound Name Lintuzumab Bi-213 Discontinued in Phase 1/2 [166]
Synonyms
Bismab-A (TN)
    Click to Show/Hide
External Link
TTD: D0S1LE
 Compound Name HuM-195-Bi-213 Discontinued in Phase 1/2 [166]
Synonyms
SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195
    Click to Show/Hide
External Link
TTD: D0IJ1D
 Compound Name CER-227185 Discontinued in Phase 1/2 [167]
Synonyms
TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis
    Click to Show/Hide
External Link
TTD: D01CEQ
 Compound Name Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes Phase 0 [168]
External Link
TTD: D0H8UT
 Compound Name ATA2321 Preclinical [169]
External Link
TTD: DI2X8V
 Compound Name 2-D08 Preclinical [170]
Synonyms
144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE
    Click to Show/Hide
External Link
CID: 22507438
TTD: D4UFT5
 Compound Name CAR-T cells targeting CD117 Preclinical [163]
External Link
TTD: D0TS2B
 Compound Name CAR-T cells targeting CD123 Preclinical [163]
External Link
TTD: D0N4VG
 Compound Name CAR-T cells targeting Mucl Preclinical [163]
External Link
TTD: D0JW9E
 Compound Name CAR-T cells targeting CD33 Preclinical [163]
External Link
TTD: D0JT0U
 Compound Name CAR-T cells targeting CD34 Preclinical [163]
External Link
TTD: D08ABX
 Compound Name CAR-T cells targeting CD133 Preclinical [163]
External Link
TTD: D04JSI
 Compound Name CEP-4186 Terminated [171]
Synonyms
CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma
    Click to Show/Hide
External Link
TTD: D0T9SJ
 Compound Name BI 7273 Investigative [172]
Synonyms
BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221
    Click to Show/Hide
External Link
CID: 118796358
TTD: DVZ6M1
 Compound Name G3139 + cytarabine (ARA-C) Investigative [173]
External Link
CID: 91865905
TTD: D0XU9F
 Compound Name G3139 + Fludarabine Investigative [173]
External Link
CID: 91865905
TTD: D0LM3T
 Compound Name CG-1255 Investigative [174]
Synonyms
CG-1552; Histone deacetylase inhibitors, CircaGen
    Click to Show/Hide
External Link
TTD: D0J3QN
 Compound Name AC-501 Investigative [174]
External Link
TTD: D0E1UY
 Compound Name AKN-028 Investigative [175]
Synonyms
Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska
    Click to Show/Hide
External Link
CID: 44177328
TTD: D0D0TQ
DrugBank: DB12746
 Compound Name VLIM-88 Investigative [174]
External Link
TTD: D0B1TN
 Compound Name G3139 + G-CSF Investigative [173]
External Link
CID: 91865905
TTD: D0B0HK
 Compound Name Anti-CD44 mab Investigative [174]
Synonyms
Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma
    Click to Show/Hide
External Link
TTD: D0A9JA
 Compound Name SB-559457 Investigative [176]
External Link
TTD: D09WOY
 Compound Name COTI-001 Investigative [174]
Synonyms
COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies
    Click to Show/Hide
External Link
TTD: D04BXH
 Compound Name Rebelex Investigative [174]
Synonyms
Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D01UJS
References
Ref 1 ALKBH5 modulates m6A modification to enhance acute myeloid leukemia resistance to adriamycin. Biomol Biomed. 2025 Apr 3;25(5):1038-1051. doi: 10.17305/bb.2024.11076.
Ref 2 Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. doi: 10.1038/s41573-020-00108-x. Epub 2021 Jan 19.
Ref 3 Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81. doi: 10.1016/j.molcel.2007.01.017.
Ref 4 Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med Chem Lett. 2014 Jan 2;5(2):205-9. doi: 10.1021/ml400496h. eCollection 2014 Feb 13.
Ref 5 Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem. 2010 Aug 12;53(15):5844-57. doi: 10.1021/jm100478y.
Ref 6 A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol. 2012 Jul 20;7(7):1152-7. doi: 10.1021/cb300139y. Epub 2012 Apr 30.
Ref 7 Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013 Nov 14;56(21):8931-42. doi: 10.1021/jm401480r. Epub 2013 Oct 31.
Ref 8 A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011 Jul 10;7(8):566-74. doi: 10.1038/nchembio.599.
Ref 9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 10 2017 FDA drug approvals. Nat Rev Drug Discov. 2018 Feb;17(2):81-85. doi: 10.1038/nrd.2018.4. Epub 2018 Jan 19.
Ref 11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
Ref 12 ClinicalTrials.gov (NCT02502968) BL-8040 Addition to Consolidation Therapy in AML Patients.
Ref 13 2018 FDA drug approvals. Nat Rev Drug Discov. 2019 Feb;18(2):85-89. doi: 10.1038/d41573-019-00014-x.
Ref 14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5151).
Ref 16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7621).
Ref 17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
Ref 19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6775).
Ref 21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6845).
Ref 22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063).
Ref 23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
Ref 24 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Ref 25 ClinicalTrials.gov (NCT04778397) Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2). U.S. National Institutes of Health.
Ref 26 ClinicalTrials.gov (NCT02665065) Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA). U.S. National Institutes of Health.
Ref 27 ClinicalTrials.gov (NCT02999854) Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (HATCY). U.S. National Institutes of Health.
Ref 28 ClinicalTrials.gov (NCT04571645) Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML). U.S. National Institutes of Health.
Ref 29 ClinicalTrials.gov (NCT01006252) A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma. U.S. National Institutes of Health.
Ref 30 ClinicalTrials.gov (NCT01866930) Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naive Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV. U.S. National Institutes of Health.
Ref 31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8086).
Ref 32 ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health.
Ref 33 ClinicalTrials.gov (NCT01147939) Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML). U.S. National Institutes of Health.
Ref 34 ClinicalTrials.gov (NCT02545283) A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (MIRROS). U.S. National Institutes of Health.
Ref 35 ClinicalTrials.gov (NCT04229979) GPS Compared With BAT in AML CR2/CR2p. U.S. National Institutes of Health.
Ref 36 ClinicalTrials.gov (NCT02273739) Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation. U.S.National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT01303796) A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 38 ClinicalTrials.gov (NCT01478178) Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma. U.S. National Institutes of Health.
Ref 39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011613)
Ref 40 ClinicalTrials.gov (NCT00093990) Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
Ref 41 ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
Ref 42 ClinicalTrials.gov (NCT00522834) Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma. U.S. National Institutes of Health.
Ref 43 ClinicalTrials.gov (NCT03616470) Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 44 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7729).
Ref 45 Therapeutic Vaccines against Cancer: Clinical trials of therapeutic vaccines in cancer patients yield positive results. OncoLog, August 2010, Vol.55, No.8.
Ref 46 ClinicalTrials.gov (NCT01191801) Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML (VALOR). U.S. National Institutes of Health.
Ref 47 ClinicalTrials.gov (NCT03699475) Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE). U.S. National Institutes of Health.
Ref 48 ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
Ref 49 ClinicalTrials.gov (NCT04395092) Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). U.S. National Institutes of Health.
Ref 50 ClinicalTrials.gov (NCT03301597) NLA101 in Adults Receiving High Dose Chemotherapy for AML (LAUNCH). U.S. National Institutes of Health.
Ref 51 ClinicalTrials.gov (NCT03110354) DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL). U.S. National Institutes of Health.
Ref 52 ClinicalTrials.gov (NCT04827719) BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS. U.S. National Institutes of Health.
Ref 53 ClinicalTrials.gov (NCT04511130) A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation. U.S.National Institutes of Health.
Ref 54 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7958).
Ref 55 ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
Ref 56 ClinicalTrials.gov (NCT01416389) A Study of LY2523355 in Patients With Breast Cancer. U.S. National Institutes of Health.
Ref 57 Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12.
Ref 58 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7885).
Ref 59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040574)
Ref 60 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5666).
Ref 61 ClinicalTrials.gov (NCT01463696) Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650). U.S. National Institutes of Health.
Ref 62 Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
Ref 63 ClinicalTrials.gov (NCT03760666) A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 64 ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
Ref 65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032443)
Ref 66 ClinicalTrials.gov (NCT00210470) A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer. U.S. National Institutes of Health.
Ref 67 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8270).
Ref 68 ClinicalTrials.gov (NCT02481297) Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Ref 69 ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 70 The enhancement of phase 2 enzyme activities by sodium butyrate in normal intestinal epithelial cells is associated with Nrf2 and p53. Mol Cell Biochem. 2012 Nov;370(1-2):7-14.
Ref 71 ClinicalTrials.gov (NCT00510133) A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML). U.S. National Institutes of Health.
Ref 72 ClinicalTrials.gov (NCT03050216) QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML. U.S. National Institutes of Health.
Ref 73 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022187)
Ref 74 Clinical pipeline report, company report or official report of Asterias.
Ref 75 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 437).
Ref 76 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 77 Iomab-B for Hematopoetic Stem Cells Transplantation. Pipeline report of Actinium Pharmaecuticals. 2012.
Ref 78 ClinicalTrials.gov (NCT00559871) Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease. U.S. National Institutes of Health.
Ref 79 ClinicalTrials.gov (NCT00544674) PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 80 ClinicalTrials.gov (NCT00363649) Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI. U.S. National Institutes of Health.
Ref 81 ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health.
Ref 82 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7708).
Ref 83 ClinicalTrials.gov (NCT01687387) Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR). U.S. National Institutes of Health.
Ref 84 ClinicalTrials.gov (NCT04079296) A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
Ref 85 ClinicalTrials.gov (NCT04477291) A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 86 ClinicalTrials.gov (NCT04067336) First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 87 ClinicalTrials.gov (NCT03594955) First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome. U.S. National Institutes of Health.
Ref 88 ClinicalTrials.gov (NCT03850574) Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 89 ClinicalTrials.gov (NCT03176277) A Study of ONO-7475 in Patients With Acute Leukemias. U.S. National Institutes of Health.
Ref 90 ClinicalTrials.gov (NCT03194685) Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 91 ClinicalTrials.gov (NCT02113982) SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 92 ClinicalTrials.gov (NCT03008187) SEL24/MEN1703 in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 93 ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Ref 94 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
Ref 95 ClinicalTrials.gov (NCT04284228) Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT. U.S. National Institutes of Health.
Ref 96 ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
Ref 97 ClinicalTrials.gov (NCT01606579) Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies. U.S. National Institutes of Health.
Ref 98 ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
Ref 99 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021304)
Ref 100 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017917)
Ref 101 ClinicalTrials.gov (NCT02028455) A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Ref 102 ClinicalTrials.gov (NCT03701295) Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement. U.S. National Institutes of Health.
Ref 103 ClinicalTrials.gov (NCT00397579) DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes. U.S. National Institutes of Health.
Ref 104 ClinicalTrials.gov (NCT04493619) PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. U.S. National Institutes of Health.
Ref 105 ClinicalTrials.gov (NCT03055286) Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients. U.S. National Institutes of Health.
Ref 106 ClinicalTrials.gov (NCT04372706) RTX-240 Monotherapy. U.S. National Institutes of Health.
Ref 107 Clinical pipeline report, company report or official report of Genus 0ncology.
Ref 108 ClinicalTrials.gov (NCT02303782) A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT). U.S. National Institutes of Health.
Ref 109 CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018 Jul 24;2(14):1738-1749.
Ref 110 ClinicalTrials.gov (NCT03841110) FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 111 ClinicalTrials.gov (NCT03705858) Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 112 ClinicalTrials.gov (NCT03927261) A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients With CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome. U.S.National Institutes of Health.
Ref 113 ClinicalTrials.gov (NCT03516760) Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 114 ClinicalTrials.gov (NCT04702425) VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma). U.S. National Institutes of Health.
Ref 115 ClinicalTrials.gov (NCT04021368) SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome. U.S. National Institutes of Health.
Ref 116 ClinicalTrials.gov (NCT04623944) NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults With AML or MDS. U.S. National Institutes of Health.
Ref 117 ClinicalTrials.gov (NCT05086315) An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). U.S.National Institutes of Health.
Ref 118 ClinicalTrials.gov (NCT04372433) IO-202 as Monotherapy in Patients in AML and CMML. U.S. National Institutes of Health.
Ref 119 ClinicalTrials.gov (NCT03884829) A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS. U.S. National Institutes of Health.
Ref 120 ClinicalTrials.gov (NCT03564288) Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
Ref 121 ClinicalTrials.gov (NCT04282668) A Study of TAS1440 With ATRA in Subjects With r/r AML. U.S. National Institutes of Health.
Ref 122 Clinical pipeline report, company report or official report of Roche
Ref 123 ClinicalTrials.gov (NCT04402541) Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome. U.S. National Institutes of Health.
Ref 124 ClinicalTrials.gov (NCT05712278) A Phase I, Single-arm, Open Label, Dose Escalation, Multicenter Study of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). U.S.National Institutes of Health.
Ref 125 ClinicalTrials.gov (NCT03483324) Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation. U.S. National Institutes of Health.
Ref 126 ClinicalTrials.gov (NCT04139434) Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
Ref 127 ClinicalTrials.gov (NCT02841540) A Study of H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia. U.S. National Institutes of Health.
Ref 128 ClinicalTrials.gov (NCT04156256) CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies. U.S. National Institutes of Health.
Ref 129 ClinicalTrials.gov (NCT03915379) A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
Ref 130 ClinicalTrials.gov (NCT03541369) Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528). U.S. National Institutes of Health.
Ref 131 ClinicalTrials.gov (NCT04272203) A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers. U.S. National Institutes of Health.
Ref 132 ClinicalTrials.gov (NCT02979366) Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome. U.S. National Institutes of Health.
Ref 133 ClinicalTrials.gov (NCT04614636) FT538 in Subjects With Advanced Hematologic Malignancies. U.S. National Institutes of Health.
Ref 134 ClinicalTrials.gov (NCT04771130) A Study of BGB-11417 in Participants With Myeloid Malignancies. U.S. National Institutes of Health.
Ref 135 ClinicalTrials.gov (NCT04227847) A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies. U.S. National Institutes of Health.
Ref 136 Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
Ref 137 ClinicalTrials.gov (NCT04789408) A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. U.S.National Institutes of Health.
Ref 138 ClinicalTrials.gov (NCT04167696) Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1). U.S. National Institutes of Health.
Ref 139 ClinicalTrials.gov (NCT05001451) A Phase 1, Open Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, and Preliminary Antileukemic Activity of GDX012 in Patients With Minimal Residual Disease (MRD) Positive Acute Myeloid Leukemia. U.S.National Institutes of Health.
Ref 140 ClinicalTrials.gov (NCT03647800) Study of APVO436 in Patients With AML or MDS. U.S. National Institutes of Health.
Ref 141 ClinicalTrials.gov (NCT02305563) Phase 1 Study of BMS-936564. U.S. National Institutes of Health.
Ref 142 ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Ref 143 A water soluble parthenolide analogue suppresses in vivo tumor growth of two tobacco associated cancers, lung and bladder cancer, by targeting NF- B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10): 2481-2494.
Ref 144 ClinicalTrials.gov (NCT03766126) Lentivirally Redirected CD123 Autologous T Cells in AML
Ref 145 ClinicalTrials.gov (NCT03310008) Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases
Ref 146 ClinicalTrials.gov (NCT00701324) BI 811283 in Various Solid Tumours. U.S. National Institutes of Health.
Ref 147 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753)
Ref 148 ClinicalTrials.gov (NCT02040506) A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML. U.S. National Institutes of Health.
Ref 149 ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Ref 150 ClinicalTrials.gov (NCT00981240) Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes. U.S. National Institutes of Health.
Ref 151 ClinicalTrials.gov (NCT03114670) Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Ref 152 ClinicalTrials.gov (NCT01632852) A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission. U.S. National Institutes of Health.
Ref 153 ClinicalTrials.gov (NCT03797261) A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies. U.S. National Institutes of Health.
Ref 154 ClinicalTrials.gov (NCT03126864) Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Ref 155 ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
Ref 156 ClinicalTrials.gov (NCT02416466) CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
Ref 157 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040360)
Ref 158 ClinicalTrials.gov (NCT00887926) Study of EB10 in Patients With Leukemia. U.S. National Institutes of Health.
Ref 159 ClinicalTrials.gov (NCT00363454) Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer. U.S. National Institutes of Health.
Ref 160 ClinicalTrials.gov (NCT01051063) Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy. U.S. National Institutes of Health.
Ref 161 ClinicalTrials.gov (NCT03585517) Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
Ref 162 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5691).
Ref 163 ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Ref 164 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001281)
Ref 165 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005159)
Ref 166 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008571)
Ref 167 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026293)
Ref 168 ClinicalTrials.gov (NCT02623582) CD123 Redirected Autologous T Cells for AML
Ref 169 Clinical pipeline report, company report or official report of Atara Biotherapeutics.
Ref 170 2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2. Biochem Biophys Res Commun. 2019 Jun 11;513(4):1063-1069.
Ref 171 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012493)
Ref 172 Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75.
Ref 173 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
Ref 174 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 175 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7969).
Ref 176 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).